{"name": "Millennium Pharmaceuticals",
 "permalink": "millennium-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/millennium-pharmaceuticals",
 "homepage_url": "http://www.mlnm.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 966,
 "founded_year": 1993,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@mlnm.com",
 "phone_number": "800-390-5663",
 "description": "Biopharm research",
 "created_at": "Mon Sep 07 10:20:49 UTC 2009",
 "updated_at": "Thu Jul 14 13:51:41 UTC 2011",
 "overview": "\u003Cp\u003EMillennium Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of medicines for the treatment of cancer in the United States and internationally. It develops and markets VELCADE for injection, a cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. \u003C/p\u003E\n\n\u003Cp\u003EThe company was founded in 1993 and is headquartered in Cambridge, Massachusetts with facilities in San Diego, San Francisco, Tsukuba, and Osaka. \u003C/p\u003E\n\n\u003Cp\u003EAs of May 13, 2008, Millennium Pharmaceuticals, Inc. operates as a subsidiary of Takeda Pharmaceutical Co. Ltd.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       51],
      "assets/images/resized/0005/8968/58968v1-max-150x150.png"],
     [[177,
       61],
      "assets/images/resized/0005/8968/58968v1-max-250x250.png"],
     [[177,
       61],
      "assets/images/resized/0005/8968/58968v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Deborah",
      "last_name": "Dunsire",
      "permalink": "deborah-dunsire",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Marsha",
      "last_name": "H. Fanucci",
      "permalink": "marsha-h-fanucci",
      "image": null}},
   {"is_past": false,
    "title": "COO and CFO",
    "person":
     {"first_name": "Kevin",
      "last_name": "Starr",
      "permalink": "kevin-starr",
      "image": null}},
   {"is_past": true,
    "title": "Scientist, Group Leader Diabetes Program",
    "person":
     {"first_name": "Giulia",
      "last_name": "C. Kennedy",
      "permalink": "giulia-c-kennedy",
      "image":
       {"available_sizes":
         [[[100,
            130],
           "assets/images/resized/0026/4106/264106v1-max-150x150.jpg"],
          [[100,
            130],
           "assets/images/resized/0026/4106/264106v1-max-250x250.jpg"],
          [[100,
            130],
           "assets/images/resized/0026/4106/264106v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "Senior Director of Neurobiology",
    "person":
     {"first_name": "Peter",
      "last_name": "S. DiStefano",
      "permalink": "peter-s-distefano-ph-d",
      "image":
       {"available_sizes":
         [[[150,
            150],
           "assets/images/resized/0027/1855/271855v1-max-150x150.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/1855/271855v1-max-250x250.jpg"],
          [[200,
            200],
           "assets/images/resized/0027/1855/271855v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition":
  {"price_amount": 8689310000.0,
   "price_currency_code": "USD",
   "term_code": null,
   "source_url": "http://www.takeda.com/press/article_29939.html",
   "source_description": "Takeda Completes Acquisition of Millennium",
   "acquired_year": 2008,
   "acquired_month": 2,
   "acquired_day": 1,
   "acquiring_company":
    {"name": "Takeda Pharmaceutical",
     "permalink": "takeda-pharmaceutical",
     "image":
      {"available_sizes":
        [[[82,
           32],
          "assets/images/resized/0005/9044/59044v2-max-150x150.png"],
         [[82,
           32],
          "assets/images/resized/0005/9044/59044v2-max-250x250.png"],
         [[82,
           32],
          "assets/images/resized/0005/9044/59044v2-max-450x450.png"]],
       "attribution": null}}},
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "40 Landsdowne Street",
    "address2": "",
    "zip_code": "02139",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "submitted two supplemental new drug applications (NDAs) for Velcade, a cancer treatment, to the U.S. Food and Drug Administration",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 26,
    "source_url": "http://www.masshightech.com/stories/2011/04/25/daily23-Millennium-submits-supplemental-NDAs-on-cancer-drug.html",
    "source_text": null,
    "source_description": "Millennium submits supplemental NDAs on cancer drug",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Millennium Pharmaceuticals",
      "permalink": "millennium-pharmaceuticals"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}